Equillium (EQ) Cash & Current Investments (2017 - 2026)
Equillium (EQ) reported Cash & Current Investments of $60.4 million for Q1 2026, up 316.48% year-over-year from $14.5 million in Q1 2025, and up 103.11% on a QoQ basis from $29.7 million in Q4 2025.
Equillium (EQ) has 10 years of Cash & Current Investments data on file, last reported at $60.4 million in Q1 2026.
- Quarterly Cash & Current Investments rose 316.48% year-over-year to $60.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.4 million (up 316.48% YoY) and the FY2025 annual result came in at $29.7 million, up 31.71% from the prior year.
- Cash & Current Investments advanced to $60.4 million in Q1 2026 per EQ's latest filing, from $29.7 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $71.0 million in Q4 2022 and bottomed at $11.5 million in Q2 2025.
- The 5-year median for Cash & Current Investments is $40.9 million (2023), against an average of $41.3 million.
- The widest annual swing landed in 2025, when Cash & Current Investments plunged 65.48%; it then jumped 316.48% in 2026.
- Tracing EQ's Cash & Current Investments over 5 years: stood at $71.0 million in 2022, then sank by 42.46% to $40.9 million in 2023, then plunged by 44.76% to $22.6 million in 2024, then surged by 31.71% to $29.7 million in 2025, then surged by 103.11% to $60.4 million in 2026.
- Per Business Quant, the three latest EQ Cash & Current Investments figures stand at $60.4 million (Q1 2026), $29.7 million (Q4 2025), and $33.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Equillium | 279.21 Mn | 218.82 Mn | - | 60.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.39 Mn |
| Dec 31, 2025 | 29.73 Mn |
| Sep 30, 2025 | 33.12 Mn |
| Jun 30, 2025 | 11.50 Mn |
| Mar 31, 2025 | 14.50 Mn |
| Dec 31, 2024 | 22.58 Mn |
| Sep 30, 2024 | 25.88 Mn |
| Jun 30, 2024 | 33.30 Mn |
| Mar 31, 2024 | 32.29 Mn |
| Dec 31, 2023 | 40.87 Mn |
| Sep 30, 2023 | 46.31 Mn |
| Jun 30, 2023 | 48.38 Mn |
| Mar 31, 2023 | 61.99 Mn |
| Dec 31, 2022 | 71.02 Mn |
| Sep 30, 2022 | 44.52 Mn |
| Jun 30, 2022 | 57.56 Mn |
| Mar 31, 2022 | 68.82 Mn |
| Dec 31, 2021 | 80.71 Mn |
| Sep 30, 2021 | 90.69 Mn |
| Jun 30, 2021 | 97.64 Mn |
| Mar 31, 2021 | 104.08 Mn |
| Dec 31, 2020 | 82.16 Mn |
| Sep 30, 2020 | 90.54 Mn |
| Jun 30, 2020 | 42.61 Mn |
| Mar 31, 2020 | 47.68 Mn |
| Dec 31, 2019 | 53.14 Mn |
| Sep 30, 2019 | 62.24 Mn |
| Jun 30, 2019 | 56.94 Mn |
| Mar 31, 2019 | 61.61 Mn |
| Dec 31, 2018 | 65.91 Mn |
| Sep 30, 2018 | 4.98 Mn |
| Dec 31, 2017 | 7.10 Mn |